c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations.
Bellon, S.F., Kaplan-Lefko, P., Yang, Y., Zhang, Y., Moriguchi, J., Rex, K., Johnson, C.W., Rose, P.E., Long, A.M., O'Connor, A.B., Gu, Y., Coxon, A., Kim, T.S., Tasker, A., Burgess, T.L., Dussault, I.(2008) J Biol Chem 283: 2675-2683
- PubMed: 18055465 
- DOI: 10.1074/jbc.M705774200
- Primary Citation of Related Structures:  
2RFN, 2RFS - PubMed Abstract: 
c-Met is a receptor tyrosine kinase often deregulated in human cancers, thus making it an attractive drug target. One mechanism by which c-Met deregulation leads to cancer is through gain-of-function mutations. Therefore, small molecules capable of targeting these mutations could offer therapeutic benefits for affected patients ...